PURPOSE: Diabetic Retinopathy is one of the worst complications of diabetes and can threaten sight. The aim of this study is to compare the visual acuity outcome in proliferative diabetic retinopathy(PDR) with clinically detectable macular oedema after intravitreal administration of either bevacizumab or ranibizumab. METHOD: Data were analysed retrospectively in which 80 eyes of 64 patients were enrolled. They were divided into two groups by simple random sampling, 40 PDR eyes treated with bevacizumab in group A and 40 PDR eyes treated with ranibizumab in group B. Visual acuities along with basic demographic characteristics were noted down. The changes in best corrected vision(BCVA) and the number of injections required were compared between the two groups. RESULTS: The study included 80 eyes of 64 patients, out of which 52 were phakic and 28 were pseudophakic. At the end of 1 year, in Group A 10 eyes(25%) showed no changes in visual acuity, 29 eyes(72.5%) showed improvement between LogMAR 1.00 to 0.48 and 1(2.5%) showed visual acuity less than LogMAR 0.33. In Group B, 8 eyes(20%) showed no changes, 30 eyes(75%) showed improvement between LogMAR 1.00 to 0.48, 2 eye(5%) showed visual acuity less than LogMAR 0.33 Group A and Group B showed similar efcacy after same number of intravitreal injections administered and similar follow-up.CONCLUSION: Our results show that ranibizumab and bevacizumab are more or less similar in terms of visual acuity outcome. At the same time bevacizumab is more cost-effective than ranibizumab. Further trials needs to be done using bevacizumab. The success of anti-VEGF treatment depends not only on the treatment of active disease, but also on the prevention of disease of disease worsening. Planning the next anti-VEGF injection treatment helps to minimize the possibility of delays in treatment. The present covid-19 lockdown restrictions has affected in the treatment causing delay.